top of page

Who We Are

Curae Pharma360 has significant experience in developing and commercializing the medicines people need.

Staff Leadership

Andrea Olariu photo_edited_edited.jpg

Andrea Olariu, MD, PhD

Chief Executive Officer 

Andrea Olariu, MD, PhD is the CEO of Curae Pharma360 Inc. Dr. Olariu serves also as the Chief Operating Officer of Medicines360, the nonprofit parent company of Curae. At Medicines360, she led the development, approval and indication expansion strategy of the company’s flagship product, a hormonal IUD that received FDA approval in 2015, followed by several approvals in global markets. Addressing the gap in equitable access to medicines is central to Andrea’s strategic approach to setting Curae’s overall direction. Before joining Medicines360, Andrea developed and implemented clinical and regulatory strategies for several medical devices that received approval in the U.S., Canada, and the European Union. Prior to moving to the United States, Dr. Olariu worked for over 15 years in academia, as an Associate Professor of Dermatology at the University of Szeged in Szeged, Hungary and a Senior Lecturer of Immunology at the University of Medicine and Pharmacy, Timisoara in Timisoara, Romania. Dr. Olariu has authored over 40 peer-reviewed medical publications, is the recipient of several academic honors, and has spoken at national and international conferences.

Autumn_new website photo_Nov 22.jpg
Brad_New Website Photo_Nov 22.jpg
Mark_New Website Photo_Nov 22.jpg
Sooraj_New website photo_ Nov 22.jpg

Autumn Ehnow

Chief Operating Officer

Autumn Ehnow is an experienced pharmaceutical and nonprofit leader with a strong track record managing business partnerships in the U.S. and across the globe. Fueled in part by her own personal experience of distressing periods when needed medications were out of reach, she is a driving force working to create equitable access to crucial medicines. At Curae, Ehnow partners with the CEO to take primary responsibility for the evolution and execution of the operating plan to scale the Curae organization appropriately in the areas of Commercial Operations, Market Access, Marketing, Policy and Government Relationships and co-manage corporate communications. Throughout her career, Ehnow has led successful partnerships with both governmental agencies and private pharmaceutical companies, developing new medicines for both small and large molecule products. She has spent 10 years at for-profit pharmaceutical companies and over 15 years in non-profit pharmaceutical entities. At the Institute for OneWorld Health, Ms. Ehnow was integral in forming and managing the Bill and Melinda Gates Foundation grant and the multi-company partnership that brought semi-synthetic Artemisinin to market. As part of the original founding team of Medicines360, she helped define and lead the program strategy and implementation that brought the hormonal IUD to market in the USA, breaking down barriers to access in the process. Ehnow continues to serve concurrently as Executive Vice President, Policy & Strategic Market Access at Medicines360, and she holds a BS in Molecular and Cellular Biology.

Brad Luke, MBA

Chief Financial Officer

Brad Luke is a senior financial executive with over thirty years of experience in finance and accounting for the pharmaceutical, healthcare, technology, and non-profit industries. Mr. Luke heads finance, accounting, human resources, and IT functions for Curae Pharma360. He previously served as the CFO at Archimedes, Inc. —  a for-profit healthcare analytics company owned by Kaiser Permanente and partially funded by the Robert Wood Johnson Foundation — as well as VP/Controller at Arcadian Health Plan — a start-up HMO in Oakland, CA. Mr. Luke received his MBA and BA in Finance from California State University, Fullerton. 

Mark Busch, PhD

Senior Vice President, Quality and Product Safety

Mark Busch brings over 25 years of experience in quality assurance/quality control, analytical, and regulatory support of GxP operations. His extensive experience includes senior-level quality positions, having served as Vice President of Quality Assurance at NeurogesX, and holding positions at Geron, VaxGen, InterMune, and Scios. As a senior quality executive, Dr. Busch has demonstrated leadership and expertise in developing and implementing quality systems to ensure GxP and regulatory compliance, supporting a broad range of pharmaceutical products throughout the product lifecycle. In addition, Dr. Busch has published several peer reviewed articles and developed his own successful pharmaceutical consulting business. Dr. Busch holds a PhD in Biological Chemistry from Indiana University and performed post-doctoral research at Carnegie Mellon University. 

Sooraj Nair

Head of Supply Chain

Sooraj Nair has over a decade of experience in leading end-to-end supply chain and product lifecycle management across various industries. He brings a unique set of skills, with his diverse background in business processes and a powerful grip on leading-edge technologies. He has led multiple cost-saving and process-enabling projects, all while improving customer service with Pepperidge Farm Inc. (part of Campbell Soup), DuPont, Fitbit & Gilead Sciences. Nair is alumni of Syracuse University and holds supply chain certificates from MIT and ASCM (formerly known as APICS). 

Emily_New website Photo_Nov 22.jpg

Emily Morris, MS, RAC-US

Head of Regulatory

Emily Morris oversees the Regulatory Department at Curae Pharma360. Her experience includes regulated drug, device, and drug-device products in the U.S., Africa, and Southeast Asia. She informs and executes regulatory strategy for product development and post-marketing, including clinical trial operations, product registration, and product lifecycle management (manufacturing, labeling, and pharmacovigilance). Morris received a Bachelor of Arts degree in Political Science and Government from Purdue University and a Master of Science degree in Strategic Regulatory Affairs from Northeastern University.  She has maintained her Regulatory Affairs Certification from the Regulatory Affairs Professional Society since 2015. 

© 2023 by Curae Pharma360 Inc.

bottom of page